Overview of rheumatic disorders

Drugs

Volumn 59, Issue SPEC. ISS. 1, 2000, Pages 1-9

  Fautrel, Bruno ^a   Bourgeois, Pierre ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; METALLOPROTEINASE; OXYGEN RADICAL; TUMOR NECROSIS FACTOR ALPHA;

CARTILAGE DEGENERATION; DISABILITY; DRUG SAFETY; HEALTH CARE COST; HUMAN; INFLAMMATORY DISEASE; OSTEOARTHRITIS; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

EID: 0034069512     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059991-00001     Document Type: Review

References (48)

1. Van den Bos G. The burden of rheumatic diseases, use of health care and life expectancies. Eur J Public Health 1995; 5: 29-34
2. Guillemin F. Les incapacités et les conséquences des maladies rhumatismales. Le J de l'AFLAR 1998; Suppl 98: 3-6
3. Pelletier JP, Di Battista JA, Roughley P, et al. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am 1993; 19: 545-68
4. Cicuttini FM, Spector TD. Osteoarthritis in the aged. Epidemiological issues and optimal management. Drugs Aging 1995; 6: 409-20
5. Hochberg MC. Development and progression of osteoarthritis. J Rheumatol 1996; 23: 1497-9
6. Chevalier X. Physiopathogenesis of arthrosis. Therapeutic perspectives [in French]. Presse Med 1998; 27: 88-92
7. Chevalier X. Physiopathogenesis of osteoarthritis. The arthritis cartilage [in French]. Presse Med 1998; 27: 81-7
8. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 1999; 7: 371-3
9. Altman RD. Various aspects of the epidemiology of osteoarthritis [in French]. Rev Rhum Ed Fr 1994; 61 (9 Pt 2): 89S-92
10. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997; 40: 598-609
11. Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997; 40: 2105-15
12. Miossec P. Cytokines and the pathophysiology of bone erosions in rheumatoid arthritis. Rev Rhum Engl Ed 1997; 64 (16 Suppl.): 89S-91
13. Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1998; 10: 187-200
14. Seldin MF, Amos CI, Ward R, et al. The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 1999; 42: 1071-9
15. Cantagrel A, Lambert N, Alam A. T cell receptor gene in synovial tissues of rheumatoid arthritis. Int Rev Immunol 1998; 17: 323-37
16. Weyand CM, Goronzy JJ. T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol 1999; 11: 210-7
17. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis [editorial; comment]. N Engl J Med 1997; 337: 195-7
18. Ruof J, Hulsemann JL, Stucki G. Evaluation of costs in rheumatic diseases: a literature review. Curr Opin Rheumatol 1999; 11: 104-9
19. Petersson IF. Occurrence of osteoarthritis of the peripheral joints in European populations. Ann Rheum Dis 1996; 55: 659-61
20. Spector TD. Epidemiology of the rheumatic diseases. Curr Opin Rheumatol 1993; 5: 132-7
21. Aho K, Kaipiainen-Seppanen O, Heliovaara M, et al. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum 1998; 27: 325-34
22. Saraux A, Guedes C, Allain J, et al. Survey of the prevalence of rheumatoid arthritis and spondylarthropathy in Brittany (France). J Rheumatol 1999. In press
23. Cimmino MA, Parisi M, Moggiana G, et al. Prevalence of rheumatoid arthritis in Italy: the Chiavari Study. Ann Rheum Dis 1998; 57: 315-8
24. Kvien TK, Glennas A, Knudsrod OG, et al. The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey. Scand J Rheumatol 1997; 26: 412-8
25. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999; 42: 415-20
26. March LM, Bachmeier CJ. Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 1997; 11: 817-34
27. Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997; 40: 1475-81
28. MacLean CH, Knight K, Paulus H, et al. Costs attributable to osteoarthritis. J Rheumatol 1998; 25: 2213-8
29. Levy E, Ferme A, Perocheau D, et al. Socioeconomic costs of osteoarthritis in France [in French]. Rev Rhum Ed Fr 1993; 60 (6 Pt 2): 63S-7
30. Mazières B. L'arthrose, problème de santé publique. Le J de l'AFLAR 1998; Suppl. 98: 11-6
31. Gabriel SE, Crowson CS, Campion ME, et al. Direct medical costs unique to people with arthritis. J Rheumatol 1997; 24: 719-25
32. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781-90
33. Albers JM, Kuper HH, van Riel PL, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999; 38: 423-30
34. Clarke AE, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24: 1051-60
35. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209-18
36. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology [see comments]. Arthritis Rheum 1995; 38: 1535-40
37. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology [see comments]. Arthritis Rheum 1995; 38: 1541-6
38. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum 1997; 26: 755-70
39. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. J Rheumatol 1997; 24: 349-57
40. Brady SJ, Brooks P, Conaghan P, et al. Pharmacotherapy and osteoarthritis. Baillieres Clin Rheumatol 1997; 11: 749-68
41. Ravaud P, Moulinier L, Giraudeau B, et al. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis Rheum 1999; 42: 475-82
42. Balint G, Szebenyi B. Non-pharmacological therapies in osteoarthritis. Baillieres Clin Rheumatol 1997; 11: 795-815
43. Minor MA. Exercise in the treatment of osteoarthritis. Rheum Dis Clin North Am 1999; 25: 397-415, viii
44. Hurley MV. The role of muscle weakness in the pathogenesis of osteoarthritis. Rheum Dis Clin North Am 1999; 25: 283-98, vi
45. Pincus T. Aggressive treatment of early rheumatoid arthritis to prevent joint damage. Bull Rheum Dis 1998; 47: 2-7
46. Dubost JJ, Soubrier M, Sauvezie B. [Treatment of rheumatoid polyarthritis: evolution of concepts and strategies]. Rev Med Interne 1999; 20: 171-8
47. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group [see comments]. N Engl J Med 1995; 333: 142-6
48. Ryan L, Brooks P. Disease-modifying antirheumatic drugs. Curr Opin Rheumatol 1999; 11: 161-6